An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Repare Therapeutics Inc. (NASDAQ: RPTX) announced participation in the virtual 2022 Guggenheim Synthetic Lethality Day on May 16, 2022, at 9:00 a.m. ET. Senior management will engage in a fireside chat, providing insights into their precision oncology strategies. Interested parties can access a live webcast via the Investor section on their website, with an archived replay available for 90 days post-event. Repare is known for its innovative SNIPRx® platform focusing on synthetic lethality in cancer therapeutics development.
Positive
None.
Negative
None.
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the virtual 2022 Guggenheim Synthetic Lethality Day on Monday, May 16, 2022 at 9:00 a.m. Eastern Time.
A live webcast of the fireside can be accessed in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company’s website for 90 days.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate camonsertib (also known as RP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development, its second clinical candidate, RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development, a Polθ inhibitor program, as well as several early-stage, pre-clinical programs. For more information, please visit reparerx.com.
SNIPRx® is a registered trademark of Repare Therapeutics Inc.
What is the date and time of Repare Therapeutics' participation in the Guggenheim Synthetic Lethality Day?
Repare Therapeutics will participate in the virtual Guggenheim Synthetic Lethality Day on May 16, 2022, at 9:00 a.m. Eastern Time.
How can I access the webcast of the Repare Therapeutics fireside chat?
The webcast can be accessed through the Investor section of Repare Therapeutics' website at https://ir.reparerx.com/news-and-events/events.
How long will the Repare Therapeutics webcast be available for replay?
The replay of the Repare Therapeutics webcast will be archived on their website for 90 days.
What are the key focuses of Repare Therapeutics Inc. in oncology?
Repare Therapeutics focuses on precision oncology through its proprietary synthetic lethality approach, utilizing its genome-wide, CRISPR-enabled SNIPRx® platform to develop targeted cancer therapies.
What is the lead product candidate of Repare Therapeutics?
Repare Therapeutics' lead product candidate is camonsertib (RP-3500), currently in Phase 1/2 clinical development.
